Introduction of KCNH3
KCNH3, also known as potassium voltage-gated channel subfamily H (eag-related) member 3, potassium channel voltage gated eag related subfamily H member 3, ether-a-go-go K(+) channel family member, KIAA1282, or Kv12.2, is a 117.1 kDa membrane protein that is composed of 1087 amino acids. In humans, it is encoded by the KCNH3 gene which is localized at the chromosome 12q13.12. The protein produced from the KCNH3 gene is a voltage-gated potassium channel alpha subunit and contains six transmembrane domains, a pore region of voltage-gated potassium channels, a cyclic nucleotide binding (CNB) domain, and N-glycosylation sites. It is showed forebrain-preferential distribution (such as cerebral cortex, amygdala, hippocampus, and striatal regions) by a 4-kb transcript, but not observed in any other tissue examined.
|Basic Information of KCNH3|
|Protein Name||Potassium voltage-gated channel subfamily H member 3|
|Aliases||Brain-specific eag-like channel 1, BEC1, Ether-a-go-go-like potassium channel 2, ELK channel 2, ELK2, Voltage-gated potassium channel subunit Kv12.2|
|Organism||Homo sapiens (Human)|
Function of KCNH3 Membrane Protein
KCNH3 belongs to the ether-a-go-go (KCNH) family of voltage-gated potassium (K+) channels, which elicits an outward current both with transient and steady-state components voltage dependently. The transient part has fast-inactivating kinetics and the steady component reveals a bell-shaped current-voltage relationship, also observed in transcriptional regulator ERG, a member of the KCNH family. The K+ channels, mostly expressed in the central nervous system, are genetically heterogeneous and one of the determinants of neuronal excitability. The therapeutic potential of K+ channel blockers for cognitive enhancement has been reported, however, the contribution that each K+ channel gene makes to cognitive functions is still obscure. In cerebral cortexes, KCNH3 is widely present from layer II to layer VI, through specific expression in cell bodies of neurons with typical pyramidal shapes. Further investigation suggested that it is involved in cellular excitability of restricted neurons in the human central nervous system.
Fig.1 Characterization of spatial and temporal expression of Kcnh3 in the developing murine forebrain. (Vezzali, 2016)
Application of KCNH3 Membrane Protein in Literature
The goal of this review was to identify the pharmacological profiles of a KCNH3 inhibitor N-(4-fluorophenyl)-N'-phenyl-N''-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine (ASP2905) in vitro and in vivo. The findings suggested that ASP2905 as a selective, orally administered inhibitor of KCNH3 can enhance cognitive performance.
This study provided further proofs on the FOXG1/FOXO/SMAD transcription factor network. The ligands of the TGFβ- and IGF-family, Foxo1, Foxo3 and Kcnh3 as novel FOXG1-target genes were determined during telencephalic developments and demonstrated that FOXG1 interfered with the Foxo1 and TGFβ transcription.
Six genes (KCNH3, DYX1C1, CCDC144NL, LOC100506476, LOC285847, and ZNF80) were selected and a combinatorial molecular signature was built based on their expressions. This study defined a combinatorial molecular signature seemingly useful as an attracting biomarker for early detections of proliferative diabetic retinopathy in diabetes patients.
Though the expression of 25 genes was found changed significantly in the heart (increased: Kcnh3, etc; decreased: Ihh, Fgfr1, etc), only 14 genes were altered in the aorta. It was the first pharmacogenomic analysis that nitroglycerin treatment resulting in vascular nitrate tolerance differentially affected the gene expression in vascular and cardiac tissues.
This article discovered that the voltage-gated K+ channel Kv12.2 was a potent regulator of excitability in hippocampal pyramidal neurons. The genetic deletion and pharmacologic block of Kv12.2 mainly reduced the firing threshold of these neurons. And the Kv12.2-/- (also referred to Kcnh3-/-) mice revealed signs of persistent neuronal hyperexcitability.
KCNH3 Preparation Options
To harvest an intact and natural protein, we have already established mature reconstitution forms and active formats for these membrane proteins. Our available Magic™ membrane protein production platform offers varieties of options for worldwide customers to suit their needs on challenging projects. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-KCNH3 antibody development services.
As a professional institute in protein markets, Creative Biolabs has won great recognition among global users for successfully accomplished items. Here, we are proud to recommend mature one-step, customized membrane protein preparation services in demands. Please feel free to contact us for more information.
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.